FIPI

Manufacturer	MedChem Express
Category	Metabolism Cholesterol & Lipid Metabolism Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Item no.	HY-12807-5mg
Targets	Phospholipase; Autophagy
CASRN	939055-18-2
eClass 6.1	30220300
eClass 9.0	32160605
Available
Alias	5-Fluoro-2-indolyl deschlorohalopemide
Purity	99.82
Product Description	FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research[1][2][3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	421.47
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 14.67 mg/mL (ultrasonic; warming)
Manufacturers Target	Autophagy; Phospholipase
Pathway	Autophagy; Metabolic Enzyme/Protease

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12807-5mg-safety-datasheet.pdf